Here are four things to know.
1. Pfizer first said it was contemplating strategic options for the unit Oct. 10.
2. Pfizer Consumer Healthcare, which sells common over-the-counter products like Advil, Centrum and ChapStick, represents one of the biggest OTC healthcare products businesses in the world and carries a potential $15 billion-plus price tag.
3. Sources said several companies, including GlaxoSmithKline and Reckitt Benckiser, have already expressed interest in the consumer health unit. Other potential bidders include Procter & Gamble, Sanofi, Johnson & Johnson and Nestle, according to the sources.
4. The auction process will likely extend through next year, with a deal being reached near the middle of 2018, a source told Reuters.
More articles on supply chain:
Pharma’s lobbying efforts: 10 drugmakers that spent the most so far in 2017
FDA announces steps, new guidance to nurture medical device innovations: 4 things to know
Express Scripts sees revenue slip 3% in Q3
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
